W. S. Harris, M. Miller, A. P. Tighe, M. H. Davidson and E. J. Schaefer, “Omega-3 Fatty Acids and Coronary Heart Disease Risk: Clinical and Mechanistic Perspectives,” Atherosclerosis, Vol. 197, No. 1, 2008, pp. 12-24. doi:10.1016/j.atherosclerosis.2007.11.008

[13]   B. E. Phillipson, D. W. Rothrock, W. E. Connor, W. S. Harris and D. R. Illingworth, “Reduction of Plasma Lipids, Lipoprotein, and Apoproteins by Dietary Fish Oils in Patients with Hypertriglyceridemia,” New England Journal of Medicine, Vol. 312, No. 19, 1985, pp. 1210-1216. doi:10.1056/NEJM198505093121902

[14]   E. B. Schmidt and J. Dyerberg, “Omega-3 Fatty Acids. Current Status in Cardiovascular Medicine,” Drugs, Vol. 47, No. 3, 1994, pp. 405-424. doi:10.2165/00003495-199447030-00003

[15]   W. S. Harris, “Nonpharmacologic Treatment of Hypertriglyceridemia: Focus on Fish Oils,” Clinical Cardiology, Vol. 22, No. 6 (Supplement), 1999, pp. 40-43.

[16]   LOVAZA Prescribing Information (Omega-3-Acid Ethyl Esters), GlaxoSmithKline, Research Triangle Park, North Carolina, 2008.

[17]   C. Cohen, E. DeJesus, A. LaMarca, et al., “Similar Virologic and Immunologic Efficacy with Fosamprenavir Boosted with 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial,” HIV Clinical Trials, Vol. 11, No. 5, 2010, pp. 239-247. doi:10.1310/hct1105-239

[18]   D. A. Parks, H. C. Jennings, C. Taylor, G. E. Pakes and E. P. Acosta, “Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics before and after Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II),” HIV Clinical Trials, Vol. 10, No. 3, 2009, pp. 160-167. doi:10.1310/hct1003-160

[19]   C. B. Hicks, E. DeJesus, L. M. Sloan, et al., “Comparison of Once-Daily Fosamprenavir Boosted with either 100 or 200 mg of Ritonavir, in Combination with Abacavir/ Lamivudine: 96-Week Results from COL100758,” AIDS Research and Human Retroviruses, Vol. 25, No. 4, 2009, pp. 395-403. doi:10.1089/aid.2008.0231

[20]   L. D. Brown, T. T. Cai and A. DasGupta, “Confidence Intervals for a Binomial Proportion and Asymptotic Expansions,” The Annals of Statistics, Vol. 30, No. 1, 2002, pp. 160-201.

[21]   P. De Truchis, M. Kirstetter, A. Perier, et al., “Reduction in Triglyceride Level with N-3 Polyunsaturated Fatty Acids in HIV-Infected Patients Taking Potent Antiretroviral Therapy: A Randomized Prospective Study,” Journal of Acquired Immune Deficiency Syndromes, Vol. 44, No. 3, 2007, pp. 278-285. doi:10.1097/QAI.0b013e31802c2f3d

[22]   J. G. Gerber, D. W. Kitch, C. J. Fichtenbaum, et al., “Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186,” Journal of Acquired Immune Deficiency Syndromes, Vol. 47, No. 4, 2008, pp. 459-466. doi:10.1097/QAI.0b013e31815bace2

[23]   H. Bays, “Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids,” American Journal of Cardiology, Vol. 98, No. 4A, 2006, pp. 71i-76i. doi:10.1016/j.amjcard.2005.12.029

[24]   D. Skiest, C. Cohen, H. Khanlou, et al., “Randomized Comparison of Darunavir/r Versus Atazanavir/r on Serum Lipids in HIV-Infected Persons on Fully suppressive lopinavir/r or fosamprenavir/r with high Serum Triglycerides. Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r (LARD),” Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 February-2 March 2011, poster 817.

[25]   E. A. Stein and G. L. Myers for the National Cholesterol Education Program Working Group on Lipoprotein Measurement, “National Cholesterol Education Program Recommendations for Triglyceride Measurement: Executive Summary,” Clinical Chemistry, Vol. 41, No. 10, 1995, pp. 1421-1426.

 
 
Top